Sub-optimal response in schizophrenia is frequent, warranting augmentation strategies over treatment-as-usual (TAU). We assessed nutraceuticals/phytoceutical augmentation strategies via network meta-analysis. Randomized controlled trials in schizophrenia/schizoaffective disorder were identified via the following databases: PubMed, MEDLINE, EMBASE, Scopus, PsycINFO, CENTRAL, and ClinicalTrials.gov. Change (Standardized Mean Difference = SMD) in total symptomatology and acceptability (Risk Ratio = RR) were co-primary outcomes. Secondary outcomes were positive, negative, cognitive, and depressive symptom changes, general psychopathology, tolerability, and response rates. We conducted subset analyses by disease phase and sensitivity analyses by risk of bias and assessed global/local inconsistency, publication bias, risk of bias, and confidence in the evidence. The systematic review included 49 records documenting 50 studies (n = 2384) documenting 22 interventions. Citicoline (SMD =-1.05,95%CI = -1.85; -0.24), L-lysine (SMD = -1.04,95%CI = -1.84; -0.25), N-acetylcysteine (SMD = -0.87, 95%CI = -1.27; -0.47) and sarcosine (SMD = -0.5,95%CI = -0.87-0.13) outperformed placebo for total symptomatology. High heterogeneity (tau = 0.10, I = 55.9%) and global inconsistency (Q = 40.79, df = 18, p = 0.002) emerged without publication bias (Egger's test, p = 0.42). Sarcosine improved negative symptoms (SMD = -0.65, 95%CI = -1.10; -0.19). N-acetylcysteine improved negative symptoms (SMD = -0.90, 95%CI = -1.42; -0.39)/general psychopathology (SMD = -0.76, 95%CI = -1.39; -0.13). No compound improved total symptomatology within acute phase studies (k = 7, n = 422). Sarcosine (SMD = -1.26,95%CI = -1.91; -0.60), citicoline (SMD = -1.05,95%CI = -1.65;-0.44), and N-acetylcysteine (SMD = -0.55,95%CI = -0.92,-0.19) outperformed placebo augmentation in clinically stable participants. Sensitivity analyses removing high-risk-of-bias studies confirmed overall findings in all phases and clinically stable samples. In contrast, the acute phase analysis restricted to low risk-of-bias studies showed a superior effect vs. placebo for N-acetylcysteine (SMD = -1.10, 95%CI = -1.75,-0.45), L-lysine (SMD = -1.05,95%CI = -1.55, -0.19), omega-3 fatty acids (SMD = -0.83,95%CI = -1.31, -0.34) and withania somnifera (SMD = -0.71,95%CI = -1.21,-0.22). Citicoline (SMD = -1.05,95%CI = -1.86,-0.23), L-lysine (SMD = -1.04,95%CI = -1.84,-0.24), N-acetylcysteine (SMD = -0.89,95%CI = -1.35,-0.43) and sarcosine (SMD = -0.61,95%CI = -1.02,-0.21) outperformed placebo augmentation of TAU ("any phase"). Drop-out due to any cause or adverse events did not differ between nutraceutical/phytoceutical vs. placebo+TAU. Sarcosine, citicoline, and N-acetylcysteine are promising augmentation interventions in stable patients with schizophrenia, yet the quality of evidence is low to very low. Further high-quality trials in acute phases/specific outcomes/difficult-to-treat schizophrenia are warranted.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41380-024-02645-yDOI Listing

Publication Analysis

Top Keywords

total symptomatology
12
outperformed placebo
12
systematic review
8
network meta-analysis
8
augmentation strategies
8
sensitivity analyses
8
risk bias
8
publication bias
8
improved negative
8
negative symptoms
8

Similar Publications

Patients with obstructive sleep apnea (OSA), restless legs syndrome (RLS), or both may exhibit varied manifestations of depressive and anxiety symptomatology, reflecting the complex interplay between sleep disturbances, neurotransmitter imbalances, and psychosocial stressors in these often overlapping conditions. The aim of this study was to compare depressive and anxiety symptomatology, insomnia severity, and sleepiness in these conditions. Patients were enrolled and subdivided into those with OSA, RLS, and OSA + RLS.

View Article and Find Full Text PDF

Structural Study of Anxiety and Mood-related Symptomatology in Psychiatric Outpatients.

Rev Colomb Psiquiatr (Engl Ed)

December 2024

M.D., M.P.H., Psychiatrist, Department of Psychiatry and Psychology, Mayo Clinic School of Medicine, Rochester, MN, USA; Universidad Peruana Cayetano Heredia, Lima, Peru.

Introduction: Knowledge of the symptomatological structure of mental disorders is relevant for their understanding and classification. In the absence of previous Latin American research on the simultaneous structural exploration of various types of psychiatric symptomatologies, the objective of this study is to examine the structure of anxious and mood-related symptoms, resulting syndromes, and their correlations.

Method: Several instruments for the evaluation of anxious, depressive, and manic symptoms were administered to 305 psychiatric outpatients.

View Article and Find Full Text PDF

Gallbladder disease is a frequent indication for non-obstetric surgical intervention during pregnancy. Gallbladder perforation (GBP) during pregnancy is an uncommon but severe pathology that usually requires immediate attention, and it represents a challenge for surgeons. We present the case of a GBP in a pregnant patient alongside a discussion of available surgical approaches.

View Article and Find Full Text PDF

DSM-5 acute stress disorder in hospitalized burn patients: The impact and interplay of pre- and peri-trauma psychological risk factors.

Burns

December 2024

Graduate Institute of Behavioral Sciences, Chang Gung University, Taoyuan, Taiwan; Department of Psychiatry, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan. Electronic address:

Objective: Burn injuries can be traumatic and lead to psychological sequelae, particularly acute stress disorder (ASD). Information regarding the prevalence and risk factors of ASD following DSM-5 criteria is relatively limited among survivors of burn and other traumas. This study aimed to investigate the prevalence of probable ASD post-burn according to DSM-5 criteria and explore the impact and interplay of pre- and peri-trauma psychological risk factors on DSM-5 ASD symptomatology.

View Article and Find Full Text PDF

Background: Reproductive health conditions such as polycystic ovary syndrome (PCOS), endometriosis, and uterine fibroids pose a significant burden to people who menstruate, health care systems, and economies. Despite clinical guidelines for each condition, prolonged delays in diagnosis are commonplace, resulting in an increase to health care costs and risk of health complications. Symptom checker apps have the potential to significantly reduce time to diagnosis by providing users with health information and tools to better understand their symptoms.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!